Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical Companies has submitted a marketing application to the FDA for ponesimod for adults with relapsing multiple sclerosis (MS).
MS is a chronic autoimmune inflammatory disorder of the central nervous system (CNS). Ponesimod modulates a protein called sphingosine-1-phosphate receptor 1 (S1P1) that reduces the number of circulating lymphocytes by trapping them in the lymph nodes which reduces the number of the pro-inflammatory cells that can cross into the CNS thereby dampening inflammation.
